Indian Pharma Exodus: Why Export Slump to $287 Million Sparks Deep Concerns Over China Market Friction

Indian Pharma Exodus: Why Export Slump to $287 Million Sparks Deep Concerns Over China Market Friction​

Indian pharmaceutical exports face growing headwinds in the Chinese market, a crucial international foothold for domestic drug manufacturers. Shipments to China contracted by 11.54 percent in FY26, falling to $287.42 million from $324.91 million in FY25. This sharp contraction signals significant difficulties in penetrating the world's second-largest pharmaceutical market.

While this decline is alarming for exporters, the broader picture of India's pharma industry remains robust. Overall Indian pharmaceutical exports grew by 2 percent to reach $31 billion during the same period. Despite this national growth, the slide in the Chinese market highlights mounting operational and regulatory challenges specific to the relationship between Indian and Chinese drugmakers.

Why China is a "Country of Concern" for Exporters​

The core friction points causing the export slump stem primarily from non-tariff barriers and rigid domestic regulations within China. Industry insiders have pointed out that China's healthcare landscape heavily favors local manufacturers, creating substantial hurdles for Indian formulations.

Regulatory approval processes in China are notably slow, a point raised by the head of a pharma industry body who wished to remain anonymous. Major Indian drugmakers such as Sun Pharma, Dr Reddy's, and Cipla have actively sought opportunities within this market. Efforts like winning bids to supply generics to public hospitals in China were met with diminishing returns.

Aggressive cost undercutting from domestic Chinese manufacturers combined with India’s heavy reliance on raw materials imported from China has priced Indian firms out of the competitive sphere. The combination of these factors is intensifying the difficulties for Indian pharmaceutical companies attempting to scale up their operations there.

Assessing Pharmaceutical Import Dependency on China​

Despite export struggles, India's reliance on China as a supply chain partner remains extensive and significant. DGCIS data indicates that China continues to be India’s top source country for pharmaceutical imports by a wide margin, accounting for 38.09 percent of total imports in FY25.

The volume metrics underline the fragility of India's pharma infrastructure when it comes to global supply chains. Imports from China contracted slightly by 3.43 percent, moving from $3.8 billion in FY25 to $3.7 billion in FY26. A substantial portion of these imports pertain to bulk drugs and intermediates, raw materials necessary for finished dosage manufacturing.

These essential active ingredients currently represent a massive 46.54 percent share of India's total pharmaceutical imports, valued at $4.5 billion. China maintains its dominance as the primary supplier for these critical ingredients required in medicine production within India.

Path Forward: Strategies to Improve Market Engagement​

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is pushing for heightened engagement and collaborative efforts as a strategy to strengthen the market presence of Indian companies in China. Industry experts suggest that finished dosage formulation manufacturers should explore formal reverse trade arrangements, possibly guided by government oversight.

One suggested mechanism involves tying API imports from China directly to Beijing procuring Finished Dosage Formulations (FDFs) from India. This arrangement would need to cover between 25 percent and 50 percent of the imported API volume.

Pharmexcil chairman Namit Joshi noted that stronger industry-to-industry engagement, a more predictable market access mechanism, and continuous regulatory cooperation are vital steps required to enhance pharmaceutical trade stability moving forward.